Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Relapsed/Refractory Pediatric Hepatocellular Carcinoma
NCT04134559Phase 2Recruiting
- Start
- Nov 2020
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC). Started Nov 2020; status: recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04134559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134559.